Aadi Bioscience Q3 2024 Earnings Report

Aadi Bioscience EPS Results

• Actual EPS: -$0.46
• Consensus EPS: -$0.46
• Beat/Miss: Met Expectations
• One Year Ago EPS: -$0.60

Aadi Bioscience Revenue Results

• Actual Revenue: $7.21 million
• Expected Revenue: $6.55 million
• Beat/Miss: Beat by +$660.00 thousand
• YoY Revenue Growth: N/A

Aadi Bioscience Announcement Details

• Quarter: Q3 2024
• Date: 11/6/2024
• Time: Before Market Opens
• Conference Call Date: Wednesday, November 6, 2024
• Conference Call Time: 4:00PM ET

Aadi Bioscience (NASDAQ:AADI) is a precision oncology company dedicated to developing targeted therapies for patients with genomically defined cancers. Founded in 2016 and headquartered in Cambridge, Massachusetts, the company focuses on identifying molecular drivers of tumor growth and crafting novel agents that address those specific genetic alterations. Aadi Bioscience completed its initial public offering in 2018 and trades on the Nasdaq under the ticker symbol AADI.

The company’s lead commercial product, FYARRO™ (nab-sirolimus), is an investigational mTOR inhibitor formulated using nanoparticle albumin-bound technology. FYARRO is approved by the U.S. Food and Drug Administration for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumors (PEComas). Beyond its current indication, Aadi Bioscience is advancing FYARRO in multiple clinical trials targeting other rare and difficult-to-treat cancers, including breast cancer, renal cell carcinoma and other solid tumors harboring mTOR pathway dysregulation.

In addition to its commercial efforts, Aadi maintains a robust research and development organization that collaborates with academic institutions and global clinical sites. The company’s pipeline includes next-generation mTOR inhibitors and combination strategies designed to overcome resistance mechanisms and expand the therapeutic reach of its products. Aadi Bioscience conducts studies across North America and Europe, leveraging its expertise in biomarker-driven drug development to accelerate patient enrollment and deliver insights into tumor biology.

Under the leadership of President and Chief Executive Officer Manmeet S. Walia, Ph.D., Aadi Bioscience continues to build its capabilities in precision medicine, regulatory affairs and commercial operations. The management team combines deep scientific knowledge with extensive industry experience, guiding the company’s mission to bring personalized cancer therapies to patients with limited treatment options.